| Anemia in chronic kidney disease
Jesduvroq vs Retacrit
Side-by-side clinical, coverage, and cost comparison for anemia in chronic kidney disease.Deep comparison between: Jesduvroq vs Retacrit with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRetacrit has a higher rate of injection site reactions vs Jesduvroq based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Retacrit but not Jesduvroq, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Jesduvroq
Retacrit
At A Glance
Oral
Daily
HIF-PH inhibitor
SC or IV injection
3 times weekly or weekly
Erythropoiesis-stimulating agent (ESA)
Indications
- Anemia in chronic kidney disease
- Anemia in chronic kidney disease
- Anemia co-occurrent with human immunodeficiency virus infection
- Anemia due to and following chemotherapy
Dosing
Anemia in chronic kidney disease (ESA-naive, on dialysis) Once daily oral; starting dose 4 mg if hemoglobin <9 g/dL, 2 mg if >=9 to <=10 g/dL, or 1 mg if >10 g/dL; reduce starting dose by half with moderate hepatic impairment (Child-Pugh Class B) or concomitant moderate CYP2C8 inhibitor; maximum dose 24 mg once daily.
Anemia in chronic kidney disease (switching from ESA, on dialysis) Once daily oral; starting dose 4 mg for prior epoetin alfa <=2,000 units/week equivalent, 6 mg for >2,000 to <10,000, 8 mg for >=10,000 to <20,000, or 12 mg for >=20,000 units/week; reduce starting dose by half with moderate hepatic impairment or concomitant moderate CYP2C8 inhibitor; maximum dose 24 mg once daily.
Anemia in chronic kidney disease Adults: 50-100 Units/kg 3 times weekly IV or SC (IV recommended for hemodialysis); pediatric patients (>= 1 month): 50 Units/kg 3 times weekly IV or SC; individualize maintenance dose.
Anemia co-occurrent with human immunodeficiency virus infection 100 Units/kg IV or SC 3 times weekly; increase by 50-100 Units/kg at 4- to 8-week intervals if no response after 8 weeks; maximum 300 Units/kg 3 times weekly.
Anemia due to and following chemotherapy Adults: 150 Units/kg SC 3 times weekly or 40,000 Units SC weekly until completion of chemotherapy course; pediatric patients (5-18 years): 600 Units/kg IV weekly until completion of chemotherapy course.
Surgery patients 300 Units/kg SC daily for 15 days (10 days pre-surgery, day of surgery, 4 days post-surgery) or 600 Units/kg SC weekly for 4 doses administered 21, 14, and 7 days before surgery and on the day of surgery.
Contraindications
- Concomitant use of a strong CYP2C8 inhibitor (e.g., gemfibrozil)
- Uncontrolled hypertension
- Uncontrolled hypertension
- Pure red cell aplasia (PRCA) that begins after treatment with RETACRIT or other erythropoietin protein drugs
- Serious allergic reactions to RETACRIT or other epoetin alfa products
- Use of multiple-dose vials (benzyl alcohol formulation) in neonates, infants, pregnant women, and lactating women
Adverse Reactions
Most common (>=10%) Hypertension, thrombotic vascular events, abdominal pain
Serious Death, myocardial infarction, stroke, venous thromboembolism, vascular access thrombosis, heart failure hospitalization, hypertension, gastrointestinal erosion
Most common (>=5%) Hypertension, arthralgia, nausea, vomiting, pyrexia, rash, muscle spasm, dizziness, cough, myalgia, headache, pruritus, injection site pain
Serious Increased mortality, myocardial infarction, stroke, thromboembolism, tumor progression or recurrence, hypertension, seizures, PRCA, serious allergic reactions, severe cutaneous reactions
Postmarketing Seizures, PRCA, serious allergic reactions, injection site reactions (irritation and pain), porphyria, severe cutaneous reactions
Pharmacology
Daprodustat is a reversible inhibitor of HIF-PH1, PH2, and PH3, stabilizing HIF-1alpha and HIF-2alpha transcription factors and increasing transcription of HIF-responsive genes including erythropoietin, thereby stimulating red blood cell production in a dose-dependent manner.
Epoetin alfa-epbx is an erythropoiesis-stimulating agent (ESA) that stimulates erythropoiesis by the same mechanism as endogenous erythropoietin, increasing reticulocyte count within 10 days and raising RBC count, hemoglobin, and hematocrit within 2 to 6 weeks.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Jesduvroq
- Covered on 5 commercial plans
- PA (7/12) · Step Therapy (4/12) · Qty limit (0/12)
Retacrit
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (9/12) · Qty limit (10/12)
UnitedHealthcare
Jesduvroq
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Retacrit
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Jesduvroq
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Retacrit
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Jesduvroq.
Cost estimate not availableHealthWell: Hepatitis C
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
JesduvroqView full Jesduvroq profile
RetacritView full Retacrit profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.